# Safe Use of Immune Checkpoint Inhibitors in Patients With Autoimmune Disease in a Community Hospital Setting: A Report of Two Cases

## TL;DR

This paper reports two cases where immune checkpoint inhibitors were safely used in cancer patients with autoimmune diseases.

## Contribution

It provides real-world evidence supporting the safe use of ICIs in selected autoimmune disease patients.

## Key findings

- Two patients with autoimmune diseases received ICIs with manageable toxicities.
- The patients achieved desirable oncologic outcomes.
- The findings support expanding ICI use to autoimmune disease patients.

## Abstract

Immune checkpoint inhibitors (ICIs) are fundamental to the management of hematologic and solid organ malignancies, and indications for their use are rapidly increasing. Patients with preexisting autoimmune diseases are often excluded from clinical trials involving ICIs due to the risk of exacerbating the underlying autoimmune condition. The lack of trial-level safety data limits the use of these therapies in real-world patients with autoimmune disease. We present a case series of two patients with preexisting autoimmune diseases who received immunotherapy for their malignancies, with manageable toxicities and desirable outcomes from an oncologic standpoint. We aim to contribute to the growing body of evidence suggesting that ICIs can be safely offered to selected patients with autoimmune diseases.